Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity

The human CYP2A6 enzyme metabolizes certain drugs and pre‐carcinogens and appears to be the most important enzyme for nicotine metabolism. At present, more than 10 different allelic variants are known that cause abolished or decreased enzyme activity. Genetic polymorphism in this gene might be of particular importance for an individual's need for nicotine and for susceptibility to lung and/or liver cancer. We have identified a new CYP2A6 allele (CYP2A6*12) which carries an unequal crossover between the CYP2A6 and CYP2A7 genes in intron 2. This results in a hybrid allele where the 5′ regulatory region and exons 1–2 are of CYP2A7 origin and exons 3–9 are of CYP2A6 origin, resulting in 10 amino acid substitutions compared to the CYP2A6*1 allele. Phenotyping with the CYP2A6 substrate coumarin indicates that it causes reduced CYP2A6 activity in'vivo. Furthermore, when expressed in mammalian COS‐1 cells, the enzyme variant catalyzed 7‐hydroxylation of coumarin at a rate approximately 60% of that of the wild‐type enzyme. The CYP2A6*12 allele was present at an allele frequency of 2.2% among Spaniards, but was absent in Chinese. Hum Mutat 20:275–283, 2002.© 2002 Wiley‐Liss, Inc.

[1]  J. Idle,et al.  Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6 , 1998, European Journal of Clinical Pharmacology.

[2]  F. Gonzalez,et al.  Organization and evolution of the cytochrome P450 CYP2A-2B-2F subfamily gene cluster on human chromosome 19 , 1995, Journal of Molecular Evolution.

[3]  T. Kamataki,et al.  A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. , 1999, The Journal of pharmacology and experimental therapeutics.

[4]  Paavo Honkakoski,et al.  High variability of nitrosamine metabolism among individuals: Role of cytochromes P450 2A6 and 2E1 in the dealkylation of N‐nitrosodimethylamine and N‐nitrosodiethylamine in mice and humans , 1993, Molecular carcinogenesis.

[5]  P. Souček.  Novel sensitive high-performance liquid chromatographic method for assay of coumarin 7-hydroxylation. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[6]  Y. Funae,et al.  A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). , 1998, Pharmacogenetics.

[7]  M. Ingelman-Sundberg,et al.  Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: evolutionary, toxicological, and clinical pharmacological aspects. , 1999, Drug metabolism reviews.

[8]  J. Idle,et al.  The role of individual human cytochromes P450 in drug metabolism and clinical response. , 1992, Trends in pharmacological sciences.

[9]  M. Kitagawa,et al.  CYP2A6*6, a Novel Polymorphism in Cytochrome P450 2A6, Has a Single Amino Acid Substitution (R128Q) That Inactivates Enzymatic Activity* , 2001, The Journal of Biological Chemistry.

[10]  O. Pelkonen,et al.  CYP2A6: a human coumarin 7-hydroxylase. , 2000, Toxicology.

[11]  T Yamamoto,et al.  Nicotine metabolism and CYP2A6 allele frequencies in Koreans. , 2001, Pharmacogenetics.

[12]  F. Gonzalez,et al.  The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. , 1990, Biochemistry.

[13]  O. Pelkonen,et al.  Interindividual variability of coumarin 7-hydroxylation in a Turkish population , 2004, European Journal of Clinical Pharmacology.

[14]  H. Jörnvall,et al.  Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. , 1989, The Journal of biological chemistry.

[15]  M. Oscarson.  Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[16]  O Pelkonen,et al.  A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. , 1995, American journal of human genetics.

[17]  Hiroshi Yamamoto,et al.  Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans , 2001, Clinical pharmacology and therapeutics.

[18]  H. Yamazaki,et al.  Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[19]  M. Waterman,et al.  Microsomal p450s use specific proline-rich sequences for efficient folding, but not for maintenance of the folded structure. , 2001, Journal of biochemistry.

[20]  J. Gilmore,et al.  Identification of a 43-kDa protein in human liver cytosol that binds to the 3'-untranslated region of CYP2A6 mRNA. , 2001, Biochemical pharmacology.

[21]  O. Pelkonen,et al.  Hepatitis A impairs the function of human hepatic CYP2A6 in vivo. , 1997, Toxicology.

[22]  O Pelkonen,et al.  Polymorphisms of CYP2A6 and its practical consequences. , 2001, British journal of clinical pharmacology.

[23]  T. Shimada,et al.  Purification and characterization of human liver microsomal cytochrome P-450 2A6. , 1991, Molecular pharmacology.

[24]  S. Anttila,et al.  Expression of CYP2A genes in human liver and extrahepatic tissues. , 1999, Biochemical pharmacology.

[25]  K. Kitagawa,et al.  The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. , 1999, Biochemical and biophysical research communications.

[26]  O Pelkonen,et al.  Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism , 1999, FEBS letters.

[27]  J. Stengård,et al.  Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C‐oxidase , 1998, FEBS letters.

[28]  M. Ingelman-Sundberg,et al.  Characterisation and PCR‐based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population , 1999, FEBS letters.

[29]  J. S. Miles,et al.  Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. , 1990, The Biochemical journal.

[30]  J. Yokota,et al.  CYP2A6 gene deletion reduces susceptibility to lung cancer. , 1999, Biochemical and biophysical research communications.

[31]  J. Idle,et al.  A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. , 1997, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[32]  M. Ingelman-Sundberg,et al.  Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. , 1994, Molecular pharmacology.

[33]  M. Ingelman-Sundberg,et al.  Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. , 2001, Biochemical and biophysical research communications.

[34]  O Pelkonen,et al.  Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. , 1992, Pharmacogenetics.

[35]  M. Ingelman-Sundberg,et al.  Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles. , 2000, Pharmacogenetics.

[36]  M. Ingelman-Sundberg,et al.  Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine , 2004, European Journal of Clinical Pharmacology.

[37]  B. Green,et al.  Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method. , 1999, Pharmacogenetics.